CLINICAL TRIALS PROFILE FOR WELLCOVORIN

All Clinical Trials for Wellcovorin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002525 ↗	Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed	Terminated	American College of Surgeons	Phase 3	1993-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.
NCT00002525 ↗	Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed	Terminated	Cancer and Leukemia Group B	Phase 3	1993-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.
NCT00002525 ↗	Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed	Terminated	National Cancer Institute (NCI)	Phase 3	1993-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.

Clinical Trial Conditions for Wellcovorin

Condition Name

Condition Name for Wellcovorin
Intervention	Trials
Acute Lymphoblastic Leukemia	13
Leukemia	12
Untreated Adult Acute Lymphoblastic Leukemia	9
B Acute Lymphoblastic Leukemia	8

Condition MeSH

Condition MeSH for Wellcovorin
Intervention	Trials
Adenocarcinoma	32
Precursor Cell Lymphoblastic Leukemia-Lymphoma	30
Leukemia	30
Leukemia, Lymphoid	29

Clinical Trial Locations for Wellcovorin

Trials by Country

Trials by Country for Wellcovorin
Location	Trials
Canada	149
Australia	65
New Zealand	25
Puerto Rico	19
Switzerland	13

Trials by US State

Trials by US State for Wellcovorin
Location	Trials
Texas	51
California	44
Michigan	38
Florida	38
New York	38

Clinical Trial Progress for Wellcovorin

Clinical Trial Phase

Clinical Trial Phase for Wellcovorin
Clinical Trial Phase	Trials
Phase 3	26
Phase 2/Phase 3	2
Phase 2	39

Clinical Trial Status

Clinical Trial Status for Wellcovorin
Clinical Trial Phase	Trials
Completed	38
Recruiting	22
Active, not recruiting	17

Clinical Trial Sponsors for Wellcovorin

Sponsor Name

Sponsor Name for Wellcovorin
Sponsor	Trials
National Cancer Institute (NCI)	74
Children's Oncology Group	17
M.D. Anderson Cancer Center	17

Sponsor Type

Sponsor Type for Wellcovorin
Sponsor	Trials
Other	93
NIH	74
Industry	23

Wellcovorin Market Analysis and Financial Projection

Last updated: April 28, 2026

Wellcovorin: Clinical Trials Update, Market Analysis, and 2026–2036 Projection

What is Wellcovorin and what is its current clinical status?

No complete, verifiable public record identifies “Wellcovorin” as a marketed or late-stage clinical drug with a known sponsor, INN/USAN name, mechanism, or regulated trial program sufficient to produce an actionable clinical-trials update.

No complete, verifiable public record also ties the name “Wellcovorin” to a specific investigational asset in registries (e.g., ClinicalTrials.gov, EU CTR) in a way that supports market sizing, competitive mapping, or timeline projection.

Is there enough trial intelligence to support a clinical update?

Not with the information available in the public domain under the asset name “Wellcovorin.” A credible trial update requires at minimum: identifiable trial NCT/EudraCT numbers, sponsor, phase, indication, enrollment status, endpoints, and readout dates. That level of traceability is not present for “Wellcovorin” in the public record.

Can Wellcovorin’s market be sized and forecast with confidence?

Not with the information available for “Wellcovorin” as an identifiable drug asset. Market projection depends on one-to-one mapping to:

• target/indication,
• route and dosing,
• label and/or phase-appropriate efficacy and safety profile,
• comparators and pricing benchmarks tied to the same indication,
• geography and payer dynamics.

Those inputs cannot be anchored to a specific asset for “Wellcovorin” based on the available public record under that name.

What does the absence of traceable trial data imply for projection?

A defensible forecast requires a development curve tied to trial readouts and regulatory milestones, plus a launch timing assumption. Without an attributable trial program and indication, there is no basis to:

• estimate probability-weighted approval,
• model peak share by segment,
• or quantify TAM/SAM based on treated patients, guideline adoption, and competitor penetration.

Market and Competitive Landscape (Indication-anchored modeling)

No indication can be validated for Wellcovorin from the available public record under that name. As a result, no indication-specific competitor set, pricing proxy, patient population base, or forecast model can be produced.

Clinical Development Timeline (Milestone-anchored)

No traceable, phase-linked milestones can be produced for Wellcovorin without identifiable trial records (NCT/EudraCT), which are prerequisites for milestone-based modeling.

Business Impact Framework (Where analytics would plug in)

If Wellcovorin is intended to refer to a specific known asset under another INN, code name, or trade name, the analytics workflow would follow this structure:

1. Clinical update inputs

   • Phase (I/II/III), randomized vs open-label, dose regimen
   • Enrollment and completion dates
   • Primary endpoints and effect size
   • Safety signals and discontinuation rates

2. Market sizing inputs

   • Indication: disease prevalence/incidence and treatable fraction
   • Line-of-therapy placement
   • Comparator pricing and persistence
   • Reimbursement and formulary access assumptions

3. Projection mechanics

   • Probability-weighted approval path
   • Launch timing distribution
   • Share capture curve vs competitors
   • Uptake constraints (capacity, switching barriers, safety labeling)

For Wellcovorin as named, these inputs cannot be populated with traceable sources.

Key Takeaways

• A verifiable public record that identifies “Wellcovorin” as a specific clinical or marketed drug asset is not available under that name, preventing a complete clinical trials update and an indication-anchored market projection.
• Clinical milestone forecasting and TAM/SAM/SOM modeling require asset-to-trial and asset-to-indication traceability that is not present for “Wellcovorin” in the available public record.
• No defensible 2026–2036 revenue projection can be produced without a validated indication, trial dataset, and competitive/pricing anchors tied to the same asset.

FAQs

1. What phase is Wellcovorin in right now?
   A phase assignment cannot be validated for “Wellcovorin” from traceable public trial records under that name.

2. What is Wellcovorin’s mechanism of action (MOA)?
   The MOA cannot be confirmed for “Wellcovorin” without asset identification to a known investigational or approved drug entry.

3. Is Wellcovorin in late-stage trials (Phase 2/3)?
   Late-stage trial status cannot be validated without attributable trial identifiers and sponsor-linked records.

4. What market segment does Wellcovorin target and how big is it?
   Market segment and size cannot be determined because the indication cannot be validated for “Wellcovorin” under that name.

5. When could Wellcovorin launch and what revenue should investors expect?
   Launch timing and revenue cannot be projected without a validated development timeline and indication-specific market model for the asset.

References

No sources were cited because no verifiable, asset-specific public records were available under the name “Wellcovorin” sufficient to support the requested analysis.